To see all protocols that comply with the WHO Essential Medicine List 

Welcome to eviQ

A free resource of evidence-based, consensus driven cancer treatment protocols and information for use at the point of care. eviQ is developed for the Australian context and supports health professionals in the delivery of cancer treatments.

Find out more


Latest news

View all news

Carboplatin has been reclassified as moderately emetogenic and antiemetics updated in the relevant protocols. Dexamethasone premedication dose has been reduced in taxane protocols with netupitant. Refer to ID 7 and attached PDF for more information.

The United Kingdom Chemotherapy Board has published Good Practice Guideline for Immuno-Oncology Medicines. These guidelines are designed to give a practical framework for the safe introduction and ongoing use of immunotherapy in existing Systemic Anti-Cancer Therapy (SACT) services.

The eviQ and eviQ Education teams are currently recruiting three content author positions. Click the link to find out details.

A NEW template has been published allowing for a single protocol with multiple indications. The first example is ID 3555 metastatic nivolumab for melanoma, NSCLC and RCC (weight based dosing). A flat dosing nivolumab protocol is currently under development.